{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T04:02:54Z","timestamp":1746676974347,"version":"3.40.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,6]]},"DOI":"10.7759\/cureus.83607","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T03:15:58Z","timestamp":1746587758000},"source":"Crossref","is-referenced-by-count":0,"title":["Complete Response in Recurrent End-Stage Pancreatic Cancer After Combined Immune Cell Therapy of \u03b1-Galactosylceramide Dendritic Cell Vaccine Therapy, Wilms\u2019 Tumor 1 Dendritic Cell Vaccine and Natural Killer Cell Therapy"],"prefix":"10.7759","author":[{"given":"Keibun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yamahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib L","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014, 74:2913-21. 10.1158\/0008-5472.CAN-14-0155","journal-title":"Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2318","article-title":"Strategies for increasing pancreatic tumor immunogenicity","volume":"23","author":"Johnson BA III","year":"2017","unstructured":"Johnson BA III, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for increasing pancreatic tumor immunogenicity. Clin Cancer Res. 2017, 23:1656-69. 10.1158\/1078-0432.CCR-16-2318","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa T","year":"2016","unstructured":"Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016, 388:73-85. 10.1016\/S0140-6736(16)00141-0","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu B","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KT, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024, 9:175. 10.1038\/s41392-024-01856-7","journal-title":"Signal Transduct Target Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park W","year":"2021","unstructured":"Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. JAMA. 2021, 326:851-62. 10.1001\/jama.2021.13027","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot VP","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, et al.. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018, 267:936-45. 10.1097\/SLA.0000000000002234","journal-title":"Ann Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman AD","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020, 20:651-68. 10.1038\/s41577-020-0306-5","journal-title":"Nat Rev Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47320","article-title":"WT1 dendritic cell vaccine therapy improves immune profile and prolongs progression-free survival in end-stage lung cancer","volume":"15","author":"Nagai H","year":"2023","unstructured":"Nagai H, Karube R. WT1 dendritic cell vaccine therapy improves immune profile and prolongs progression-free survival in end-stage lung cancer. Cureus. 2023, 15:e47320. 10.7759\/cureus.47320","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56685","article-title":"Late-stage ovarian cancer with systemic multiple metastases shows marked shrinkage using a combination of Wilms\u2019 tumor antigen 1 (WT1) dendritic cell vaccine, natural killer (NK) cell therapy, and nivolumab","volume":"16","author":"Nagai H","year":"2024","unstructured":"Nagai H, Karube R. Late-stage ovarian cancer with systemic multiple metastases shows marked shrinkage using a combination of Wilms\u2019 tumor antigen 1 (WT1) dendritic cell vaccine, natural killer (NK) cell therapy, and nivolumab. Cureus. 2024, 16:e56685. 10.7759\/cureus.56685","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49221","article-title":"Delayed-type hypersensitivity: an excellent indicator of anti-tumor immunity with Wilms\u2019 tumor 1 (WT1) dendritic cell vaccine therapy","volume":"15","author":"Nagai H","year":"2023","unstructured":"Nagai H, Karube R. Delayed-type hypersensitivity: an excellent indicator of anti-tumor immunity with Wilms\u2019 tumor 1 (WT1) dendritic cell vaccine therapy. Cureus. 2023, 15:e49221. 10.7759\/cureus.49221","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64972","article-title":"Combination of radiation therapy, Wim\u2019s tumor 1 (WT1) dendritic cell vaccine therapy, and \u03b1-galactosylceramide-pulsed dendritic cell vaccine therapy for end-stage small bowel cancer","volume":"16","author":"Nagai H","year":"2024","unstructured":"Nagai H, Chen H, Karube R, Koitabashi Y, Numata O, Yamahara K. Combination of radiation therapy, Wim\u2019s tumor 1 (WT1) dendritic cell vaccine therapy, and \u03b1-galactosylceramide-pulsed dendritic cell vaccine therapy for end-stage small bowel cancer. Cureus. 2024, 16:e64972. 10.7759\/cureus.64972","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01126","article-title":"\u03b1-GalCer and iNKT cell-based cancer immunotherapy: realizing the therapeutic potentials","volume":"10","author":"Zhang Y","year":"2019","unstructured":"Zhang Y, Springfield R, Chen S, et al.. \u03b1-GalCer and iNKT cell-based cancer immunotherapy: realizing the therapeutic potentials. Front Immunol. 2019, 10:1126. 10.3389\/fimmu.2019.01126","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000316","article-title":"Phase II study of \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer","volume":"8","author":"Toyoda T","year":"2020","unstructured":"Toyoda T, Kamata T, Tanaka K, et al.. Phase II study of \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer. J Immunother Cancer. 2020, 8:e000316. 10.1136\/jitc-2019-000316","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: making cold tumors hot","volume":"40","author":"Ullman NA","year":"2022","unstructured":"Ullman NA, Burchard PR, Dunne RF, Linehan DC. Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol. 2022, 40:2789-805. 10.1200\/JCO.21.02616","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.08.009","article-title":"Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert","volume":"86","author":"Li X","year":"2022","unstructured":"Li X, Gulati M, Larson AC, Solheim JC, Jain M, Kumar S, Batra SK. Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert. Semin Cancer Biol. 2022, 86:14-27. 10.1016\/j.semcancer.2022.08.009","journal-title":"Semin Cancer Biol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2005.00123.x","article-title":"Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC\/CCL21 along with tumor antigen against peritoneally disseminated tumor cells","volume":"96","author":"Matsuyoshi H","year":"2005","unstructured":"Matsuyoshi H, Hirata S, Yoshitake Y, et al.. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC\/CCL21 along with tumor antigen against peritoneally disseminated tumor cells. Cancer Sci. 2005, 96:889-96. 10.1111\/j.1349-7006.2005.00123.x","journal-title":"Cancer Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever MA","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, et al.. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009, 15:5323-37. 10.1158\/1078-0432.CCR-09-0737","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1586\/erv.13.22","article-title":"Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies","volume":"12","author":"Kalinski P","year":"2013","unstructured":"Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines. 2013, 12:285-95. 10.1586\/erv.13.22","journal-title":"Expert Rev Vaccines"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212339","article-title":"Dendritic cells and cancer immunotherapy: the adjuvant effect","volume":"22","author":"Nava S","year":"2021","unstructured":"Nava S, Lisini D, Frigerio S, Bersano A. Dendritic cells and cancer immunotherapy: the adjuvant effect. Int J Mol Sci. 2021, 22:12339. 10.3390\/ijms222212339","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee C","year":"2024","unstructured":"Hartupee C, Nagalo BM, Chabu CY, Tesfay MZ, Coleman-Barnett J, West JT, Moaven O. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Front Immunol. 2024, 15:1287459. 10.3389\/fimmu.2024.1287459","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.114","article-title":"Understanding of molecular mechanisms in natural killer cell therapy","volume":"47","author":"Yoon SR","year":"2015","unstructured":"Yoon SR, Kim TD, Choi I. Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med. 2015, 47:e141. 10.1038\/emm.2014.114","journal-title":"Exp Mol Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0632-8","article-title":"Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer","volume":"13","author":"Sakamoto N","year":"2015","unstructured":"Sakamoto N, Ishikawa T, Kokura S, et al.. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. 2015, 13:277. 10.1186\/s12967-015-0632-8","journal-title":"J Transl Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1509819","article-title":"PD-L1 blockade enhances anti-tumor efficacy of NK cells","volume":"7","author":"Oyer JL","year":"2018","unstructured":"Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology. 2018, 7:e1509819. 10.1080\/2162402X.2018.1509819","journal-title":"Oncoimmunology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363024-complete-response-in-recurrent-end-stage-pancreatic-cancer-after-combined-immune-cell-therapy-of--galactosylceramide-dendritic-cell-vaccine-therapy-wilms-tumor-1-dendritic-cell-vaccine-and-natural-killer-cell-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T03:15:59Z","timestamp":1746587759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363024-complete-response-in-recurrent-end-stage-pancreatic-cancer-after-combined-immune-cell-therapy-of--galactosylceramide-dendritic-cell-vaccine-therapy-wilms-tumor-1-dendritic-cell-vaccine-and-natural-killer-cell-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.83607","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}